The clinical performance is complex and often involves multiple systemic stresses. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnostic and therapeutic programs. Treatment and management of the treatment of the synthetic enzyme syndrome associated with SSA require individual development, usually including pharmacotherapy, rehabilitation interventions, regular follow-up, etc. In recent years, with the development of therapeutically oriented, immune-regulatory therapy and precision medicine, significant improvements have been made in many autoimmune and rheumatic immune disorders that have previously been difficult to treat.
Treatment requires close monitoring of therapeutic effects and adverse reactions, adapting to timely regimens according to the changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of anti-synthetase syndrome in conjunction with SSA. The platform serves China International Medical Service System, a team of domestically authoritative experts in the field of autoimmune and rheumatic immunity, to provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.